Natural killer cells have an activated profile in early Parkinson's disease

J Holbrook; B Patel; M Camacho; L Kahanawita; J Greenland; C H Williams-Gray

doi:10.1016/j.jneuroim.2023.578154

Natural killer cells have an activated profile in early Parkinson's disease

J Neuroimmunol. 2023 Sep 15:382:578154. doi: 10.1016/j.jneuroim.2023.578154. Epub 2023 Jul 24.

Authors

J Holbrook¹, B Patel², M Camacho², L Kahanawita², J Greenland², C H Williams-Gray²

Affiliations

¹ John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK. Electronic address: jh2264@medschl.cam.ac.uk.
² John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK.

PMID: 37549558
DOI: 10.1016/j.jneuroim.2023.578154

Abstract

Immune dysregulation is heavily implicated in Parkinson's disease (PD) but the role of Natural Killer (NK) cells has not been well characterised. Accumulating evidence indicates the immune response peaks early in the disease, hence this study focused on characterising NK cells in recently diagnosed PD. PBMCs were obtained from PD cases (< 2 years duration) and age-matched controls and immunophenotyped using flow cytometry. We found an increased proportion and number of NK cells (CD3-CD56+), mature cytotoxic NK cells (CD3-CD16 + CD56dim), and NK cells expressing the activation marker, NKG2D. This implies NK cells are activated in the earliest stages of PD.

Keywords: Immune system; Natural killer cells; Parkinson's disease.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

CD56 Antigen
Flow Cytometry
Humans
Killer Cells, Natural
Parkinson Disease*

Substances

CD56 Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding